Controversies regarding long-acting β2-agonists

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 4, 2011, Pages 345-354

  Khianey, Reena ^a   Oppenheimer, John ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

asthma; efficacy; long acting 2 agonists; safety

Indexed keywords

ARGININE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOCORTICOID RECEPTOR; GLYCINE; INTERLEUKIN 8; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING BETA 2 AGONIST; LONG ACTING DRUG; METHACHOLINE; SALBUTAMOL; SALMETEROL; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BIOPSY; BRONCHOSCOPY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; IN VITRO STUDY; LAVAGE; LOW DRUG DOSE; LUNG FUNCTION; MEDICAL HISTORY; MILD PERSISTENT ASTHMA; MONOTHERAPY; MORBIDITY; MORTALITY; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE RELAXATION; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AFRICAN AMERICANS; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; GENOTYPE; HUMANS; INFLAMMATION; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, GLUCOCORTICOID; TREATMENT OUTCOME;

EID: 79960845829     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328348a82e     Document Type: Review

References (66)

1. National Heart, Lung, and Blood Institute, National Asthma Education an Prevention Program Expert Panel Report 3, Guidelines for the diagnosis and management of asthma, 2007, http://www.nhlbi.nih.gov/guidelines, [Accessed 2 January 2011]
2. Akinbami L, National Center for Health Statistics, Asthma, 2003-2005, http://www.cdc.gov/nchs/data/hestat/asthma03-05/asthma03-05.htm.[Accessed 10 February 2011]
3. Center for Disease Control and Prevention, National Center for Health Statistics, Asthma, 2010, http://www.cdc.gov/nchs/fastats/asthma.htm, [Accessed 12 November 2010]
4. Global Initiative for Asthma, Global strategy for asthma management and prevention, 2009, http://www.ginasthma.org/Guidelineitem.aspl1=2&-l2= 1&intId=1561, [Accessed 21 November 2010]
5. Food and Drug Administration, Long-acting Beta2-Adrenergic Agonists, 2005, http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm151724.htm, [Accessed 18 November 2010]
6. Food and Drug Administration, FDA News Release: FDA Announces New Safety Controls for Long-Acting Beta Agonists, Medications Used to Treat Asthma, 2010, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm200931.htm, [Accessed 2 February 2011]
7. Irwin RS, Richardson ND, Side effects with inhaled corticosteroids: the physician's perception, Chest 2006; 130 (1 Suppl):41S-53S. (Pubitemid 44107235)
8. Barnes PJ, Pedersen S, Busse WW, Efficacy and safety of inhaled corticosteroids, New developments, Am J Respir Crit Care Med 1998; 157:S1-S53. (Pubitemid 28125600)
9. Pedersen S, Hansen OR, Budesonide treatment of moderate and severe asthma in children: a dose-response study, J Allergy Clin Immunol 1995; 95 (1 Pt 1):29-33.
10. Holt S, Suder A, Weatherall M, et al, Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis, Br Med J 2001; 323:253-256. (Pubitemid 32729109)
11. Bousquet J, Ben-Joseph R, Messonnier M, et al, A meta-analysis of the doseresponse relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma, Clin Ther 2002; 24:1-20. (Pubitemid 34117521)
12. Lipworth BJ, Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis, Arch Intern Med 1999; 159:941-955. (Pubitemid 29222495)
13. Greening AP, Ind PW, Northfield M, Shaw G, Added salmeterol versus higherdose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid, Allen & Hanburys Limited UK Study Group, Lancet 1994; 344:219-224. (Pubitemid 24229008)
14. Woolcock A, Lundback B, Ringdal N, Jacques LA, Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids, Am J Respir Crit Care Med 1996; 153:1481-1488. (Pubitemid 26141329)
15. Sears MR, Lotvall J, Past, present and future: beta2-adrenoceptor agonists in asthma management, Respir Med 2005; 99:152-170. (Pubitemid 40104270)
16. Linden A, Bergendal A, Ullman A, et al, Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism, Thorax 1993; 48:547-553. (Pubitemid 23160174)
17. Jeppsson AB, Kallstrom BL, Waldeck B, Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro, Pharmacol Toxicol 1992; 71:272-277.
18. Palmqvist M, Persson G, Lazer L, et al, Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency, Eur Respir J 1997; 10:2484-2489. (Pubitemid 28048620)
19. van Noord JA, Smeets JJ, Raaijmakers JA, et al, Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action, Eur Respir J 1996; 9:1684-1688. (Pubitemid 26271155)
20. Kallstrom BL, Sjoberg J, Waldeck B, The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro, Br J Pharmacol 1994; 113:687-692. (Pubitemid 24326801)
21. Palmqvist M, Ibsen T, Mellen A, Lotvall J, Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients, Am J Respir Crit Care Med 1999; 160:244-249. (Pubitemid 29326095)
22. Everden P, Campbell M, Harnden C, et al, Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids, Pediatr Allergy Immunol 2004; 15:40-47. (Pubitemid 38327298)
23. Rabe KF, Jorres R, Nowak D, et al, Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 h in bronchial asthma. Am Rev Respir Dis 1993; 147:1436-1441. (Pubitemid 23160541)
24. Barnes PJ, How corticosteroids control inflammation: Quintiles Prize Lecture 2005, Br J Pharmacol 2006; 148:245-254. (Pubitemid 43804814)
25. Barnes PJ, Efficacy of inhaled corticosteroids in asthma, J Allergy Clin Immunol 1998; 102:531-538.
26. Eickelberg O, Roth M, Lorx R, et al, Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells, J Biol Chem 1999; 274:1005-1010.
27. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al, Formoterol attenuates neutrophilic airway inflammation in asthma, Chest 2005; 128:1936-1942. (Pubitemid 41507524)
28. Overbeek SE, Mulder PG, Baelemans SM, et al, Formoterol added to lowdose budesonide has no additional antiinflammatory effect in asthmatic patients, Chest 2005; 128:1121-1127. (Pubitemid 41324385)
29. Roberts JA, Bradding P, Britten KM, et al, The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma, Eur Respir J 1999; 14:275-282. (Pubitemid 29461289)
30. Sindi A, Todd DC, Nair P, Antiinflammatory effects of long-acting beta2- agonists in patients with asthma: a systematic review and meta-analysis. Chest 2009; 136:145-154.
31. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al, Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164 (8 Pt 1):1392-1397. (Pubitemid 33124016)
32. Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM, Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children, Cochrane Database Syst Rev 2009:CD005307.
33. Pauwels RA, Lofdahl CG, Postma DS, et al, Effect of inhaled formoterol and budesonide on exacerbations of asthma, Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group, N Engl J Med 1997; 337:1405-1411.
34. O'Byrne PM, Naya IP, Kallen A, et al, Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control, Chest 2008; 134:1192-1199.
35. Sears MR, The addition of long-acting beta-agonists to inhaled corticosteroids in asthma, Curr Opin Pulm Med 2011; 17:23-28.
36. McIvor RA, Pizzichini E, Turner MO, et al, Potential masking effects of salmeterol on airway inflammation in asthma, Am J Respir Crit Care Med 1998; 158:924-930. (Pubitemid 28449462)
37. Tattersfield AE, Postma DS, Barnes PJ, et al, Exacerbations of asthma: a descriptive study of 425 severe exacerbations, The FACET International Study Group, Am J Respir Crit Care Med 1999; 160:594-599. (Pubitemid 29380678)
38. Masoli M, Weatherall M, Holt S, Beasley R, Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma, Thorax 2005; 60:730-734. (Pubitemid 41297891)
39. Shrewsbury S, Pyke S, Britton M, Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA), Br Med J 2000; 320:1368-1373. (Pubitemid 30261116)
40. Bateman ED, Boushey HA, Bousquet J, et al, Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study, Am J Respir Crit Care Med 2004; 170:836-844. (Pubitemid 39346477)
41. Barnes NC, Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study, Am J Respir Crit Care Med 2004; 170:830-831. (Pubitemid 39346475)
42. Lemanske RF Jr, Mauger DT, Sorkness CA, et al, Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids, N Engl J Med 2010; 362:975-985.
43. Lemanske RF Jr, Sorkness CA, Mauger EA, et al, Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial, J Am Med Assoc 2001; 285:2594-2603. (Pubitemid 32479899)
44. Lazarus SC, Boushey HA, Fahy JV, et al, Long-acting beta2-agonist monotherapy vs, continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial, J Am Med Assoc 2001; 285:2583-2593. (Pubitemid 32479898)
45. Martinez FD, Safety of long-acting beta-agonists: an urgent need to clear the air, N Engl J Med 2005; 353:2637-2639. (Pubitemid 41817711)
46. Wijesinghe M, Weatherall M, Perrin K, et al, Risk of mortality associated with formoterol: a systematic review and meta-analysis, Eur Respir J 2009; 34:803-811.
47. Finkelstein FN, Risks of salmeterol? N Engl J Med 1994; 331:1314.
48. Castle W, Fuller R, Hall J, Palmer J, Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment, Br Med J 1993; 306:1034-1037. (Pubitemid 23105961)
49. Nelson HS, Weiss ST, Bleecker ER, et al, The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol, Chest 2006; 129:15-26. (Pubitemid 43265239)
50. Oppenheimer J, Nelson HS, Safety of long-acting beta-agonists in asthma: a review, Curr Opin Pulm Med 2008; 14:64-69. (Pubitemid 350191040)
51. Mann M, Chowdhury B, Sullivan E, et al, Serious asthma exacerbations in asthmatics treated with high-dose formoterol, Chest 2003; 124:70-74. (Pubitemid 36851333)
52. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE, Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthmarelated deaths, Ann Intern Med 2006; 144:904-912. (Pubitemid 46768131)
53. Salpeter SR, Wall AJ, Buckley NS, Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events, Am J Med 2010; 123:322-8e2.
54. Yancey SW, Knobil K, Kral K, No association of catastrophic events with Advair, Am J Med 2010; 123:e15; author reply e7.
55. Weatherall M, Wijesinghe M, Perrin K, et al, Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy, Thorax 2010; 65:39-43.
56. Nelson H, Bonuccelli C, Radner F, et al, Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials, J Allergy Clin Immunol 2010; 125:390-6e8.
57. Basu K, Palmer CN, Tavendale R, et al, Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol, J Allergy Clin Immunol 2009; 124:1188.e3-1194.e3.
58. Green SA, Turki J, Hall IP, Liggett SB, Implications of genetic variability of human beta 2-adrenergic receptor structure, Pulm Pharmacol 1995; 8:1-10.
59. Israel E, Drazen JM, Liggett SB, et al, The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma, Am J Respir Crit Care Med 2000; 162:75-80. (Pubitemid 30469801)
60. Taylor DR, Drazen JM, Herbison GP, et al, Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55:762-767. (Pubitemid 30660904)
61. Israel E, Chinchilli VM, Ford JG, et al, Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial, Lancet 2004; 364:1505-1512. (Pubitemid 39410416)
62. Wechsler ME, Lehman E, Lazarus SC, et al, beta-Adrenergic receptor polymorphisms and response to salmeterol, Am J Respir Crit Care Med 2006; 173:519-526.
63. Bleecker ER, Postma DS, Lawrance RM, et al, Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies, Lancet 2007; 370:2118-2125. (Pubitemid 350296302)
64. Bleecker ER, Yancey SW, Baitinger LA, et al, Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma, J Allergy Clin Immunol 2006; 118:809-816. (Pubitemid 44498754)
65. Wechsler ME, Kunselman SJ, Chinchilli VM, et al, Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial, Lancet 2009; 374:1754-1764.
66. Bailey W,Castro M, Matz J, et al, Asthma exacerbations in AfricanAmericans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone, Curr Med Res Opin 2008; 24:1669-1682. (Pubitemid 351929065)